These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). ; ; ; J Hepatol; 2024 Sep; 81(3):492-542. PubMed ID: 38851997 [TBL] [Abstract][Full Text] [Related]
11. Incretin-based investigational therapies for the treatment of MASLD/MASH. Brouwers B; Rao G; Tang Y; Rodríguez Á; Glass LC; Hartman ML Diabetes Res Clin Pract; 2024 May; 211():111675. PubMed ID: 38636848 [TBL] [Abstract][Full Text] [Related]
12. NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review. Sergi CM Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126031 [TBL] [Abstract][Full Text] [Related]
13. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice. Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320 [TBL] [Abstract][Full Text] [Related]
14. Time-Restricted Feeding Attenuates Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma in Obese Male Mice. Das M; Kumar D; Sauceda C; Oberg A; Ellies LG; Zeng L; Jih LJ; Newton IG; Webster NJG Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672595 [TBL] [Abstract][Full Text] [Related]
15. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Backer S; Khanna D Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470 [TBL] [Abstract][Full Text] [Related]
16. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome. Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146 [TBL] [Abstract][Full Text] [Related]
17. Regulatory T cell: a double-edged sword from metabolic-dysfunction-associated steatohepatitis to hepatocellular carcinoma. Wang H; Tsung A; Mishra L; Huang H EBioMedicine; 2024 Mar; 101():105031. PubMed ID: 38401419 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic management of metabolic dysfunction associated steatotic liver disease. Zeng J; Fan JG; Francque SM United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865 [TBL] [Abstract][Full Text] [Related]
19. From MASH to HCC: the role of Gas6/TAM receptors. Apostolo D; Ferreira LL; Vincenzi F; Vercellino N; Minisini R; Latini F; Ferrari B; Burlone ME; Pirisi M; Bellan M Front Immunol; 2024; 15():1332818. PubMed ID: 38298195 [TBL] [Abstract][Full Text] [Related]
20. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis. Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]